 |
인쇄하기
취소
|
Boehringer Ingelheim Introduces COPD Treatment in Domestic Market
Boehringer Ingelheim Korea and Pfizer Korea announced that Spiriva HandiHaler (tiotropium bromide), for the treatment of COPD (Chronic Obstructive Pulmonary Disease), will be available in the domestic market starting February 1st.
Discovered and developed by Boehringer Ingelheim, Spiriva will be co-promoted in the domestic market by both companies, and currently the treatment is available in...
Discovered and developed by Boehringer Ingelheim, Spiriva will be co-promoted in the domestic market by both companies, and currently the treatment is available in...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.